

Figure 1 Bioinformatics analyses of the expression of NTNG gene in ovarian cancer. Volcano plots of gene expression profile in GSE45553 and GSE73935 datasets (**A**, **B**). The mRNA level of NTNG1 was higher in cisplatin-sensitive than that in cisplatin-resistant cells (**C**, **D**). Progression-free survival (PFS) in overall cases (**E**), and in the subgroup receiving cisplatin treatment (**F**): patients with a high NTNG1 level in cancer tissues had shorter PFS compared with those with a low level. *: $p < 0.05$.




Figure 2 Proteins interacted with NTNG1 in the BioGRID database.




Figure 3 NTNG1 level correlated with prognosis in EOC patients. Platinum-free interval (PFI) and Progression-free survival (PFS) in type I (n = 32; low-grade serous: 24, clear cell: 7, endometrioid: 1) (**A**, **B**) and type II cancers (n = 35; high-grade serous) (**C**, **D**). PFI and PFS in FIGO I/II (n = 22) (**E**, **F**) and FIGO III/IV cancers (n = 45) (**G**, **H**): type II or FIGO III/IV cancer patients with a high NTNG1 level in cancer tissues had shorter PFI and PFS compared with those with a low level.